Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 597Stomach Neoplasms 71Neoplasm Metastasis 56Neoplasms 35HER2-positive Breast Cancer 30Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Pathologic Complete Response 6

Interventions

pembrolizumab 7lenvatinib 3apatinib 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Carboplatin 3gallium 68 PSMA-11 2Specimen Handling 2Protons 2Nivolumab 2Epirubicin 2Cisplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tislelizumab 1regorafenib 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1abemaciclib 1Tretinoin 1Trastuzumab 1Tablets 1Sunitinib 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Adenoid Cystic × Trastuzumab × Clear all
NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Cogent Biosciences, Inc.

Phase 1 Terminated
6 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡